CRC Research Update — October 22, 2026
Today's colorectal cancer research highlights
dmmr
A collection of 116 issues
Immunotherapy resistance in dMMR colorectal cancer follows evolutionary trajectory
Skip to content
The CRC Digest
Immunotherapy resistance in dMMR colorectal cancer follows evolutionary trajectory
A review proposes that resistance evolves from early immune evasion through adaptive immunosuppression to advanced metastatic resistance with spatial heterogeneity. (Crit Rev Oncol Hematol)
This content is informational only and does not constitute medical advice.
Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancer
A multicenter cohort study of 129 patients who entered non-operative management after achieving clinical complete response with PD-1 inhibitors found 3-year disease-free survival was 96.2% with observation
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer
Skip to content
The CRC Digest
● REGULATORY
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer
The accelerated approval covers stage II or III rectal cancer and is based on the AZUR-1 trial. At median follow-up of 26.3 months, 110 of 154 patients (71%) had received dostarlimab alone,
CRC Research Update — October 20, 2026
Today's colorectal cancer research highlights
Colonoscopy screening shows differential benefit in Lynch syndrome by gene
Skip to content
The CRC Digest
▪ SCREENING
Colonoscopy screening shows differential benefit in Lynch syndrome by gene
More frequent colonoscopy screenings resulting in an increased number of adenomas detected effectively reduces CRC risk in those with a pathogenic variant in MSH2, but MLH1 carriers did not experience the same benefit;
FDA grants accelerated approval to dostarlimab for MSI-H/dMMR locally advanced rectal cancer
Skip to content
The CRC Digest
● REGULATORY
FDA grants accelerated approval to dostarlimab for MSI-H/dMMR locally advanced rectal cancer
On October 19, 2026, the FDA granted accelerated approval to dostarlimab for adults with Stage II/III locally advanced rectal cancer that is MSI-H or dMMR. The approval was based
CRC Research Update — October 16, 2026
Today's colorectal cancer research highlights
Treatment Sequencing After Immunotherapy Progression in MSI-H/dMMR Disease
Skip to content
The CRC Digest
Treatment Sequencing After Immunotherapy Progression in MSI-H/dMMR Disease
A clinical review proposes an evidence-informed framework for managing progression after immune checkpoint blockade in MSI-H/dMMR metastatic CRC, noting that BRAF V600E is common but not an absolute predictor of immunotherapy failure. (Journal of
CRC Research Update — October 14, 2026
Today's colorectal cancer research highlights